Core Viewpoint - The economic burden on patients with rare diseases is significant, and addressing this issue requires a multi-layered social mechanism rather than solely relying on individual patients [1][2]. Group 1: Rare Disease Treatment and Insurance - Biogen's Asia-Pacific President emphasizes the need for a collective approach to cover treatment costs for rare diseases, advocating for public awareness of risk-sharing and the importance of commercial insurance [1][2]. - The inclusion of diseases like ALS in insurance coverage is crucial, as 90% of ALS cases are sporadic, highlighting the need for broader public understanding and insurance participation [2]. - The role of commercial insurance is to mitigate large medical expenses, and its coverage should extend beyond just the listed drugs to effectively support patients [2]. Group 2: Biogen's Strategic Direction - Biogen is open to potential mergers and acquisitions in the Asia-Pacific region, focusing on internal innovation while also collaborating with Chinese innovative pharmaceutical companies [3]. - The company has already launched several groundbreaking treatments in China, including the first drug for spinal muscular atrophy (SMA) and a targeted drug for Alzheimer's disease [3]. - Biogen aims to achieve clinical cures for SMA and is advancing another drug in clinical trials that could significantly improve treatment outcomes [3].